 |
 |
CYTOMEDIX ANNOUNCES AVAILABILITY
OF RESEARCH REPORT ON COMPANY
ROCKVILLE, Md., Jan. 24, 2006 – Cytomedix, Inc. (AMEX: GTF),
the developer of the AutoloGel™ System for use with chronic wounds,
today announced that an updated research report about the Company
has been prepared by Crystal Research Associates.
The research report noted that as a result of rigorous and
successful clinical trials, Cytomedix plans to seek U.S. Food and
Drug Administration (FDA) clearance for its patented AutoloGel™
System for treating non-healing chronic wounds such as diabetic foot
ulcers which “would be the first blood-derived platelet releasate
therapy for the treatment of wounds that has undergone such a high
level of scrutiny and evaluation.”
Cytomedix Chairman and Chief Executive Officer Kshitij Mohan, Ph.D.,
commenting on the report, said the Company is planning to submit a
510k application for AutoloGel to the FDA during the first quarter
of 2006. “With our proprietary AutoloGel™ product targeting an
initial market of two million diabetics suffering from chronic foot
ulcers, and a strong patent portfolio that is fueling revenue growth
from licensing agreements, Cytomedix is positioning itself for
future growth,” Dr. Mohan stated.
In the original research report issued in September 2005, Crystal
Research stated that “Cytomedix has positioned itself to expand the
Company’s science and product portfolios through its significant
patent positions and through strategic relationships.” The report
noted that, “Cytomedix’s key infrastructure could enable the Company
to become a partner of choice for biotechnology and pharmaceutical
companies pursuing biological therapies.”
The original research report and its update, which were paid for by
the Company, can be accessed online at www.crystalra.com or at
www.cytomedix.com. Printed copies can be obtained by contacting The
Wall Street Group, 32 E. 57th St., New York, NY 10022, telephone
212-888-4848.
ABOUT THE COMPANIES
Cytomedix, Inc. is a biotechnology company specializing in processes
and products derived from autologous platelet releasates for uses in
chronic wounds and other applications. The current offering is the
AutoloGel™ System, a process that utilizes an autologous platelet
gel composed of multiple growth factors and fibrin matrix. Cytomedix
is working with healthcare providers to offer this advanced therapy
at the point-of-care in multiple settings. Additional information is
available at: http://www.cytomedix.com.
Statements contained in this press release not relating to
historical facts are forward-looking statements that are intended to
fall within the safe harbor rule for such statements under the
Private Securities Litigation Reform Act of 1995. The information
contained in the forward-looking statements is inherently uncertain,
and Cytomedix's actual results may differ materially due to a number
of factors, many of which are beyond Cytomedix's ability to predict
or control, including among others, the success of new sales
initiatives, governmental regulation, acceptance by the medical
community and competition. These forward-looking statements are
subject to known and unknown risks and uncertainties that could
cause actual events to differ from the forward-looking statements.
More information about some of these risks and uncertainties may be
found in the reports filed with the Securities and Exchange
Commission by Cytomedix, Inc.
SOURCE: Cytomedix, Inc.
The Wall Street Group, Inc.
Ron Stabiner
(212) 888-4848 |
|